WMT filed 4 on 2026-10-02

10 SOURCES CONFIRMED · FIRST SEEN 2026-10-02 00:00 UTC

KINDSEC Filing

DIRECTION■ Unclear/unknown

SOURCES10

ENTITIES3

STORY SIZESTANDALONE

FIRST SEEN2026-10-02 00:00 UTC

LAST UPDATE2026-10-02 00:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A Form 4 discloses insider transactions at Walmart; without share counts or prices, direction and significance cannot be assessed.

Insider filing alone carries no directional signal

CATALYST TO WATCH

Details of shares bought or sold in the filing

MAIN RISK

Missing transaction details prevent interpretation

FULL DISPATCH

WMT (CIK 0001570658) filed a 4 on 2026-10-02.

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

SUBJECTWalmart · WMT

AFFECTEDInsider Trading

AFFECTEDRetail

04 RECEIPTS

THE SOURCE RECORD.

10 SOURCES CONFIRMED

№ 01secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 02secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 03secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 04secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 05secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 06secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 07secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 08secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 09secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 10secsec.gov · PRIMARY2026-10-02 00:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.